Lancet (London, England) 2009-08-01
Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial.
ABSTRACT
BACKGROUND
Results from phase II studies in patients with stage IIIA non-small-cell lung cancer with ipsilateral mediastinal nodal metastases (N2) have shown the feasibility of resection after concurrent chemotherapy and radiotherapy with promising rates of survival. We therefore did this phase III trial to compare concurrent chemotherapy and radiotherapy followed by resection with standard concurrent chemotherapy and definitive radiotherapy without resection.
METHODS
Patients with stage T1-3pN2M0 non-small-cell lung cancer were randomly assigned in a 1:1 ratio to concurrent induction chemotherapy (two cycles of cisplatin [50 mg/m(2) on days 1, 8, 29, and 36] and etoposide [50 mg/m(2) on days 1-5 and 29-33]) plus radiotherapy (45 Gy) in multiple academic and community hospitals. If no progression, patients in group 1 underwent resection and those in group 2 continued radiotherapy uninterrupted up to 61 Gy. Two additional cycles of cisplatin and etoposide were given in both groups. The primary endpoint was overall survival (OS). Analysis was by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00002550.
FINDINGS
202 patients (median age 59 years, range 31-77) were assigned to group 1 and 194 (61 years, 32-78) to group 2. Median OS was 23.6 months (IQR 9.0-not reached) in group 1 versus 22.2 months (9.4-52.7) in group 2 (hazard ratio [HR] 0.87 [0.70-1.10]; p=0.24). Number of patients alive at 5 years was 37 (point estimate 27%) in group 1 and 24 (point estimate 20%) in group 2 (odds ratio 0.63 [0.36-1.10]; p=0.10). With N0 status at thoracotomy, the median OS was 34.4 months (IQR 15.7-not reached; 19 [point estimate 41%] patients alive at 5 years). Progression-free survival (PFS) was better in group 1 than in group 2, median 12.8 months (5.3-42.2) vs 10.5 months (4.8-20.6), HR 0.77 [0.62-0.96]; p=0.017); the number of patients without disease progression at 5 years was 32 (point estimate 22%) versus 13 (point estimate 11%), respectively. Neutropenia and oesophagitis were the main grade 3 or 4 toxicities associated with chemotherapy plus radiotherapy in group 1 (77 [38%] and 20 [10%], respectively) and group 2 (80 [41%] and 44 [23%], respectively). In group 1, 16 (8%) deaths were treatment related versus four (2%) in group 2. In an exploratory analysis, OS was improved for patients who underwent lobectomy, but not pneumonectomy, versus chemotherapy plus radiotherapy.
INTERPRETATION
Chemotherapy plus radiotherapy with or without resection (preferably lobectomy) are options for patients with stage IIIA(N2) non-small-cell lung cancer.
FUNDING
National Cancer Institute, Canadian Cancer Society, and National Cancer Institute of Canada.
Related Questions
New answer by Medical Oncologist at Rush University Medical Center (August 17, 2016)
Several recent trials have addressed management of stage III NSCLC. The intergroup 0139 trial and the EORTC 08941 trial were prospective studies of patients with known mediast...
New comment by Medical Oncologist at The Ohio State University School of Medicine ( July 14, 2022)
I would consider CheckMate 816 the clear new standard of care for these patients.
What are the major factors that impact your decision? If you opt for surgery, what factors impact your decision to offer RT preoperatively vs. postope...
New answer by Radiation Oncologist at City of Hope (June 28, 2019)
Another complication is that, at least, in my neighborhood, thoracic surgeons will NOT do thoracoscopic lobectomy and lymphadenectomy AFTER preoperative radiotherapy...
New answer by Radiation Oncologist at Yale School of Medicine (May 14, 2019)
When we initially evaluate a patient with locally advanced NSCLC, we make the decision upfront about whether the patient will be managed surgically or not, and then we stick t...
Medical inoperability is clearly defined, anatomical resectability is also pretty much clear (invasion of trachea/carina/esophagus, etc). But what abo...
New answer by at University of Michigan Medical School (June 6, 2019)
Unfortunately there is not a clearly defined criteria to answer your question. As you stated much of the debate is centered around what is "resectable N2" disease. Since there...
Should surgery followed by adjuvant chemotherapy and radiation be considered for non-bulky single station N2 disease?
New answer by Radiation Oncologist at Quillen VA Medical Center (August 23, 2016)
As the "cover story" of the exploratory analysis ran, there was an attempt to match factors of T, N and M; not specifically size, V-20, FEV1, or other clinically meanngfu; mat...
New comment by Medical Oncologist at Saint Louise Regional Hospital ( March 6, 2024)
Would you offer neoadjuvant to patients who have obvious N2 by CT, or do you reserve neoadjuvant only for patients whose N2 is defined by PET or EBUS?
And do you always exclu...